12/4
12:20 pm
gern
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
Neutral
Report
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
11/26
09:27 am
gern
Geron Corporation (NASDAQ:GERN) is favoured by institutional owners who hold 64% of the company [Yahoo! Finance]
Medium
Report
Geron Corporation (NASDAQ:GERN) is favoured by institutional owners who hold 64% of the company [Yahoo! Finance]
11/7
08:16 am
gern
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help [Seeking Alpha]
Low
Report
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help [Seeking Alpha]
11/5
12:25 pm
gern
Geron (NASDAQ:GERN) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.
Neutral
Report
Geron (NASDAQ:GERN) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.
11/5
07:00 am
gern
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Low
Report
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
11/4
08:00 am
gern
Geron Corporation to Present at Upcoming Investor Conferences
Medium
Report
Geron Corporation to Present at Upcoming Investor Conferences
11/3
09:05 am
gern
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies
Medium
Report
Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies
10/31
01:03 pm
gern
Geron (NASDAQ:GERN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Geron (NASDAQ:GERN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/27
08:00 am
gern
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025
Neutral
Report
Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025
10/23
06:14 pm
gern
GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Neutral
Report
GERON (GERN) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
10/20
05:32 pm
gern
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/15
09:35 pm
gern
Will Geron's (GERN) New Commercial Team Reshape Its Long-term Competitive Position? [Yahoo! Finance]
Medium
Report
Will Geron's (GERN) New Commercial Team Reshape Its Long-term Competitive Position? [Yahoo! Finance]
10/14
04:25 am
gern
Geron (GERN): Assessing Valuation After Leadership Changes to Drive RYTELO Growth and Strategic Transformation [Yahoo! Finance]
Medium
Report
Geron (GERN): Assessing Valuation After Leadership Changes to Drive RYTELO Growth and Strategic Transformation [Yahoo! Finance]
10/13
04:44 pm
gern
Geron Corporation Announces Executive Leadership Transitions and Appointments [Yahoo! Finance]
Medium
Report
Geron Corporation Announces Executive Leadership Transitions and Appointments [Yahoo! Finance]
10/13
04:34 pm
gern
Geron Corporation Announces Executive Leadership Transitions and Appointments
Medium
Report
Geron Corporation Announces Executive Leadership Transitions and Appointments
9/18
04:01 pm
gern
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)